Molecular Diagnosis & Therapy

, Volume 22, Issue 6, pp 683–702 | Cite as

TLR4 Polymorphisms and Expression in Solid Cancers

  • Nilesh Pandey
  • Alex Chauhan
  • Neeraj JainEmail author
Review Article


Toll-like receptors (TLRs) are a type of pattern-recognition receptor (PRR) that are part of the innate immune system known to recognize pathogen-associated molecular patterns and thereby play a crucial role in host immune response. Among the various known TLRs, TLR4 is one of the most extensively studied PRRs expressed by immune, certain nonimmune, and tumor cells. When TLR4 binds with the bacterial lipopolysaccharide, it induces production of proinflammatory cytokines, chemokines, and effector molecules as part of the immune response. Continuous exposure to pathogens and TLR4 signaling results in chronic inflammation that may further lead to malignant transformation. TLR4 is a highly polymorphic gene, and genetic variations are known to influence host immune response, leading to dysregulation of signaling pathway, which may affect an individual’s susceptibility to various diseases, including cancer. Furthermore, TLR4 expression in different tumor types may also serve as a marker for tumor proliferation, differentiation, metastasis, prognosis, and patient survival. This review aims to summarize various reports related to TLR4 polymorphisms and expression patterns and their influences on different cancer types with a special focus on solid tumors.


Compliance with Ethical Standards

Conflict of interest

Nilesh Pandey, Alex Chauhan and Neeraj Jain have no conflicts of interest that are directly relevant to the content of this article.


No sources of funding were used to conduct this study or prepare this manuscript.

Supplementary material

40291_2018_361_MOESM1_ESM.pdf (381 kb)
Supplementary material 1 (PDF 381 kb)


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.PubMedGoogle Scholar
  2. 2.
    Chen X, Liu F, Li B, Wei YG, Yan LN, Wen TF. P53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies. World J Gastroenterol. 2011;17:1211–8.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, et al. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol. 2006;100:173–8.PubMedGoogle Scholar
  4. 4.
    Zhang Z, Fu G, Wang M, Tong N, Wang S, Zhang Z. P53 codon 72 polymorphism and ovarian cancer risk: a meta-analysis. J Nanjing Med Univ. 2008;22:279–85.Google Scholar
  5. 5.
    Izmirli M. A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk. Mol Biol Rep. 2013;40:625–37.PubMedGoogle Scholar
  6. 6.
    Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol. 2006;164:297–302.PubMedGoogle Scholar
  7. 7.
    Canbay E, Eraltan IY, Cercel A, Isbir T, Gazioglu E, Aydogan F, et al. CCND1 and CDKN1B polymorphisms and risk of breast cancer. Anticancer Res. 2010;30:3093–8.PubMedGoogle Scholar
  8. 8.
    Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003;63:2033–6.PubMedGoogle Scholar
  9. 9.
    Agundez J. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 2004;5:211–24.PubMedGoogle Scholar
  10. 10.
    Chen B, Cao L, Zhou Y, Yang P, Wan HW, Jia GQ, et al. Glutathione S-transferase T1 (GSTT1) gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiologic studies. Dig Dis Sci. 2010;55:1831–8.PubMedGoogle Scholar
  11. 11.
    Huang S, Wu F, Luo M, Ma L, Gao K, Li J, et al. The glutathione S-transferase P1 341C>T polymorphism and cancer risk: a meta-analysis of 28 case–control studies. PLoS One. 2013;8:e56722.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Schröder NWJ, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005;5:156–64.PubMedGoogle Scholar
  13. 13.
    Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci. 2008;114:347–60.PubMedGoogle Scholar
  14. 14.
    El-Omar EM, Ng MT, Hold GL. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene. 2008;27:244–52.PubMedGoogle Scholar
  15. 15.
    Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2007;Chapter 14:Unit 14.12.PubMedGoogle Scholar
  16. 16.
    Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA. 1998;95:588–93.PubMedGoogle Scholar
  17. 17.
    Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373–84.PubMedGoogle Scholar
  18. 18.
    Hashimoto C, Hudson KL, Anderson KV. The Toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988;52:269–79.PubMedGoogle Scholar
  19. 19.
    Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/Cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86:973–83.PubMedGoogle Scholar
  20. 20.
    Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol. 2011;2011:609579.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Miggin SM, O’Neill LAJ. New insights into the regulation of TLR signaling. J Leukoc Biol. 2006;80:220–6.PubMedGoogle Scholar
  22. 22.
    Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57–63.PubMedGoogle Scholar
  23. 23.
    Huyton T, Rossjohn J, Wilce M. Toll-like receptors: structural pieces of a curve-shaped puzzle. Immunol Cell Biol. 2007;85:406–10.PubMedGoogle Scholar
  24. 24.
    Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.PubMedGoogle Scholar
  25. 25.
    McGettrick AF, O’Neill LAJ. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol. 2007;139:185–93.PubMedGoogle Scholar
  26. 26.
    Kurt-jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1:398.PubMedGoogle Scholar
  27. 27.
    Okumura A, Pitha PM, Yoshimura A, Harty RN. Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol. 2010;84:27–33.PubMedGoogle Scholar
  28. 28.
    Brattig NW, Bazzocchi C, Kirschning CJ, Reiling N, Buttner DW, Ceciliani F, et al. The major surface protein of Wolbachia endosymbionts in Filarial nematodes elicits immune responses through TLR2 and TLR4. J Immunol. 2004;173:437–45.PubMedGoogle Scholar
  29. 29.
    Gowda DC. TLR-mediated cell signaling by malaria GPIs. Trends Parasitol. 2007;23:596–604.PubMedGoogle Scholar
  30. 30.
    Faria MS, Calegari-Silva TC, De Carvalho Vivarini A, Mottram JC, Lopes UG, Lima APCA. Role of protein kinase R in the killing of Leishmania major by macrophages in response to neutrophil elastase and TLR4 via TNFα: and IFNβ. FASEB J. 2014;28:3050–63.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Tada H, Nemoto E, Shimauchi H, Watanabe T, Mikami T, Matsumoto T, et al. Saccharomyces cerevisiae -and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14-and Toll-like receptor 4-dependent manner. Microbiol Immunol. 2002;46:503–12.PubMedGoogle Scholar
  32. 32.
    Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010;14:2592–603.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000;164:558–61.PubMedGoogle Scholar
  34. 34.
    Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al. Toll-Like Receptor 4-dependent activation of dendritic cells by -Defensin 2. Science. 2002;298:1025–9.PubMedGoogle Scholar
  35. 35.
    Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like Receptor 4. J Exp Med. 2002;195:99–111.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmad-Nejad P, et al. The ER-resident heat shock protein Gp96 activates dendritic cells via the TLR2/4 pathway. J Biol Chem. 2002; 277:20847–53.PubMedGoogle Scholar
  37. 37.
    Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-Like Receptor 4. J Immunol. 2001;167:2887–94.PubMedGoogle Scholar
  38. 38.
    Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates toll-like receptor 4. J Biol Chem. 2001;276:10229–33.PubMedGoogle Scholar
  39. 39.
    Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-Like Receptor 4. J Immunol. 2002;168:5233–9.PubMedGoogle Scholar
  40. 40.
    Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8:487–96.Google Scholar
  41. 41.
    Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.Google Scholar
  42. 42.
    Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6:e1000010.PubMedCentralGoogle Scholar
  43. 43.
    Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase—partners in osteolytic tumor growth and metastasis. Matrix Biol. 2004;23:341–52.PubMedGoogle Scholar
  44. 44.
    Götte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006;66:10233–7.PubMedGoogle Scholar
  45. 45.
    Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–51.PubMedGoogle Scholar
  46. 46.
    O’Neill LAJ, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353–64.PubMedGoogle Scholar
  47. 47.
    Gioannini TL, Teghanemt A, Zhang D, Coussens NP, Dockstader W, Ramaswamy S, et al. Isolation of an endotoxin–MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA. 2004;101:4186–91.PubMedGoogle Scholar
  48. 48.
    Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med. 1986;164:777–93.PubMedGoogle Scholar
  49. 49.
    Wright SD, Tobias PS, Ulevitch RJ, Ramos RA. Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med. 1989;170:1231–41.PubMedGoogle Scholar
  50. 50.
    Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–3.PubMedGoogle Scholar
  51. 51.
    Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16:3–9.PubMedGoogle Scholar
  52. 52.
    Bell JK, Mullen GED, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol. 2003;24:528–33.PubMedGoogle Scholar
  53. 53.
    Johnson CM, Lyle EA, Omueti KO, Stepensky VA, Yegin O, Alpsoy E, et al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol. 2007;178:7520–4.PubMedGoogle Scholar
  54. 54.
    Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187–91.PubMedGoogle Scholar
  55. 55.
    Ferwerda B, McCall M, Verheijen K, Kullberg BJ, Van der Ven A, Van der Meer J. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med. 2008;14:1.Google Scholar
  56. 56.
    Rallabhandi P, Bell J, Boukhvalova MS, Medvedev A, Lorenz E, Arditi M, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol. 2006;177:322–32.PubMedGoogle Scholar
  57. 57.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.PubMedGoogle Scholar
  58. 58.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Multhoff G, Radons J. Radiation, inflammation, and immune responses in cancer. Front Oncol. 2012;2:1–18.Google Scholar
  60. 60.
    Yesudhas D, Gosu V, Anwar MA, Choi S. Multiple roles of toll-like receptor 4 in colorectal cancer. Front Immunol. 2014;5:1–10.Google Scholar
  61. 61.
    Zare-Bidaki M, Tsukiyama-Kohara K, Kazemi Arababadi M. Toll-like receptor 4 and hepatitis B infection: molecular mechanisms and pathogenesis. Viral Immunol. 2014;27:321–6.PubMedGoogle Scholar
  62. 62.
    Castaño-Rodríguez N, Kaakoush NO, Mitchell HM. Pattern-recognition receptors and gastric cancer. Front Immunol. 2014;5:1–23.Google Scholar
  63. 63.
    Skevaki C, Pararas M, Kostelidou K, Tsakris A, Routsias JG. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases. Clin Exp Immunol. 2015;180:165–77.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Huang H, Wu J, Jin G, Zhang H, Ding Y, Hua Z, et al. A 5′-flanking region polymorphism in toll-like receptor 4 is associated with gastric cancer in a Chinese population. J Biomed Res. 2010;24:100–6.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Wei M. TLR4 gene polymorphisms and susceptibility to gastric carcinoma and Epstein–Barr virus-associated gastric carcinoma in Northern China. Int J Sci. 2015;1:22–30.Google Scholar
  66. 66.
    Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol. 2008;154:360–4.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology. 2007;132:905–12.PubMedGoogle Scholar
  68. 68.
    de Oliveira JG, Rossi AFT, Nizato DM, Miyasaki K, Silva AE. Profiles of gene polymorphisms in cytokines and toll-like receptors with higher risk for gastric cancer. Dig Dis Sci. 2013;58:978–88.PubMedGoogle Scholar
  69. 69.
    Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI. Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer. 2007;7:70.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Kutikhin AG, Yuzhalin AE, Volkov AN, Zhivotovskiy AS, Brusina EB. Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: a case–control study. Tumor Biol. 2014;35:4821–30.Google Scholar
  71. 71.
    Huang L, Yuan K, Liu J, Ren X, Dong X, Tian W, et al. Polymorphisms of the TLR4 gene and risk of gastric cancer. Gene. 2014;537:46–50.PubMedGoogle Scholar
  72. 72.
    Castaño-Rodríguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case–control study and meta-analysis. PLoS One. 2013;8:e60327.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Castaño-Rodríguez N, Kaakoush NO, Pardo AL, Goh KL, Fock KM, Mitchell HM. Genetic polymorphisms in the Toll-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer. Hum Immunol. 2014;75:808–15.PubMedGoogle Scholar
  74. 74.
    Ohara T, Morishita T, Suzuki H, Hibi T. Heterozygous Thr135Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. Int J Mol Med. 2006;18:59–63.PubMedGoogle Scholar
  75. 75.
    Kupcinskas J, Wex T, Bornschein J, Selgrad M, Leja M, Juozaityte E, et al. Lack of association between gene polymorphisms of angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet. 2011;12:112.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Hishida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki A, Naito M, et al. Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter. 2009;14:47–53.PubMedGoogle Scholar
  77. 77.
    Qadri Q, Rasool R, Afroze D, Naqash S, Gulzar GM, Yousuf A, et al. Study of TLR4 and IL-8 gene polymorphisms in H. pylori-induced inflammation in gastric cancer in an ethnic kashmiri population. Immunol Investig. 2014;43:324–36.Google Scholar
  78. 78.
    Pimentel-Nunes P, Teixeira AL, Pereira C, Gomes M, Brandão C, Rodrigues C, et al. Functional polymorphisms of Toll-like receptors 2 and 4 alter the risk for colorectal carcinoma in Europeans. Dig Liver Dis. 2013;45:63–9.PubMedGoogle Scholar
  79. 79.
    Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, et al. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed. 2006;5:15.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Omrane I, Baroudi O, Kourda N, Bignon YJ, Uhrhammer N, Desrichard A, et al. Positive link between variant Toll-like receptor 4 (Asp299Gly and Thr399Ile) and colorectal cancer patients with advanced stage and lymph node metastasis. Tumor Biol. 2014;35:545–51.Google Scholar
  81. 81.
    Boraska Jelavić T, Barišić M, Drmic Hofman I, Boraska V, Vrdoljak E, Peruzović M, et al. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet. 2006;70:156–60.PubMedGoogle Scholar
  82. 82.
    Proença MA, de Oliveira JG, Cadamuro ACT, Succi M, Netinho JG, Goloni-Bertolo EM, et al. TLR2 and TLR4 polymorphisms influence mRNA and protein expression in colorectal cancer. World J Gastroenterol. 2015;21:7730–41.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Guo Q, Zhu J, Xia B. Polymorphism of CD14 gene but not the mutation of TLR4 gene is associated with colorectal cancer in Chinese patients. J Gastroenterol Hepatol. 2006;21:92–7.PubMedGoogle Scholar
  84. 84.
    Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control. 2009;20:1739–51.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Kopp TI, Andersen V, Tjonneland A, Vogel U. Polymorphisms in NFKB1 and TLR4 and interaction with dietary and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study. PLoS One. 2015;10:1–15.Google Scholar
  86. 86.
    Song J, Kim DY, Kim CS, Kim HJ, Lee DH, Lee HM, et al. The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet. 2009;190:88–92.PubMedGoogle Scholar
  87. 87.
    Kim HJ, Bae JS, Chang IH, Do K, Lee J, Shin HD, et al. Sequence variants of toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol. 2012;30:225–32.PubMedGoogle Scholar
  88. 88.
    Zheng SL, Augustsson-ba K, Chang B, Hedelin M, Li L, Adami H, et al. Sequence variants of Toll-Like Receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden study. Cancer Res. 2004;64:2918–22.PubMedGoogle Scholar
  89. 89.
    Balistreri CR, Caruso C, Carruba G, Miceli V, Campisi I, Listì F, et al. A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr Pharm Des. 2010;16:718–24.PubMedGoogle Scholar
  90. 90.
    Cheng I, Plummer SJ, Casey G, Witte JS. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:352–5.PubMedGoogle Scholar
  91. 91.
    Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 2005;65:11771–8.PubMedGoogle Scholar
  92. 92.
    Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response and obesity related genes with prostate cancer in CLUE II. Prostate. 2009;69:874–85.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Lindström S, Hunter DJ, Grönberg H, Stattin P, Wiklund F, Xu J, et al. Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Cancer Epidemiol Biomarkers Prev. 2010;19:873–6.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Barrett LW, Fletcher S, Wilton SD. Regulation of eukaryotic gene expression by the untranslated gene regions and other noncoding elements. Cell Mol Life Sci. 2012;69:3613–34.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Shen Y, Bu M, Zhang A, Liu Y, Fu B. Toll-like receptor 4 gene polymorphism downregulates gene expression and involves in susceptibility to bladder cancer. Tumor Biol. 2015;36:2779–84.Google Scholar
  96. 96.
    Wan B, Tan J, Zeng Q, He LY, Gan Y, Dai YB, et al. 729G/C polymorphism in Toll-like receptor 4 results in increased susceptibility to bladder cancer. Genet Mol Res. 2015;14:15482–7.PubMedGoogle Scholar
  97. 97.
    Shen Y, Liu Y, Liu S, Zhang A. Toll-like receptor 4 gene polymorphisms and susceptibility to bladder cancer. Pathol Oncol Res. 2013;19:275–80.PubMedGoogle Scholar
  98. 98.
    Singh V, Srivastava N, Kapoor R, Mittal RD. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in a case–control study with bladder cancer susceptibility in a North Indian population. Arch Med Res. 2013;44:54–61.PubMedGoogle Scholar
  99. 99.
    Pandey S, Devi R, Srivastava M, Srivastava K, Singh S, Srivastava S, et al. Gynecologic oncology impact of Toll-like receptors [TLR] 2 (−196 to −174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol Oncol. 2009;114:501–5.PubMedGoogle Scholar
  100. 100.
    Pandey N, Chauhan A, Raithatha N, Patel P, Desai A, Jain N. Absence of association between TLR4 Thr399Ile polymorphism and cervical cancer susceptibility. Meta Gene. 2018;17:249–55.Google Scholar
  101. 101.
    Zidi S, Sghaier I, Gazouani E, Mezlini A, Yacoubi-Loueslati B. Evaluation of toll-like receptors 2/3/4/9 gene polymorphisms in cervical cancer evolution. Pathol Oncol Res. 2016;22:323–30.PubMedGoogle Scholar
  102. 102.
    Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedGoogle Scholar
  103. 103.
    Lusk MJ, Konecny P. Cervicitis: a review. Curr Opin Infect Dis. 2008;21:49–55.PubMedGoogle Scholar
  104. 104.
    Zeljic K, Supic G, Jovic N, Kozomara R, Brankovic-Magic M, Obrenovic M, et al. Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Dis. 2014;20:416–24.PubMedGoogle Scholar
  105. 105.
    Song C, Chen LZ, Zhang RH, Yu XJ, Zeng YX. Functional variant in the 5′-untranslated region of Toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther. 2006;5:1285–91.PubMedGoogle Scholar
  106. 106.
    Minmin S, Xiaoqian X, Hao C, Baiyong S, Xiaxing D, Junjie X, et al. Single nucleotide polymorphisms of toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma. PLoS One. 2011;6:2–8.Google Scholar
  107. 107.
    Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer. 2010;10:382.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Yang ZH, Dai Q, Gu YJ, Guo QX, Gong L. The Toll-like receptors polymorphisms modified cytokine and chemokines is associated with nasopharyngeal carcinoma. Cancer Sci. 2012;103:1–6.Google Scholar
  109. 109.
    Etokebe GE, Knežević J, Petričević B, Pavelić J, Vrbanec DZ. Single nucleotide polymorphisms in genes encoding toll-like receptor-2,-3,-4, and-9 in case–control study with breast cancer. Genet Test Mol Biomarkers. 2009;13:729–34.PubMedGoogle Scholar
  110. 110.
    Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer. 2011;71:123–9.PubMedGoogle Scholar
  111. 111.
    Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos NV, Zagouri F, Kontogianni P, et al. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast. 2012;21:534–8.PubMedGoogle Scholar
  112. 112.
    Yang CX, Li CY, Feng W. Toll-like receptor 4 genetic variants and prognosis of breast cancer. Tissue Antigens. 2013;81:221–6.PubMedGoogle Scholar
  113. 113.
    Kurt H, Ozbayer C, Bayramoglu A, Gunes HV, Degirmenci İ, Oner KS, et al. Determination of the relationship between rs4986790 and rs4986791 variants of TLR4 gene and lung cancer. Inflammation. 2016;39:166–71.PubMedGoogle Scholar
  114. 114.
    Srivastava K, Srivastava A, Kumar A, Mittal B. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int. 2010;30:1067–72.PubMedGoogle Scholar
  115. 115.
    Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genom Inf. 2012;10:117–22.Google Scholar
  116. 116.
    Li J, Yang F, Wei F, Ren X. The role of toll-like receptor 4 in tumor microenvironment. Oncotarget. 2017;8:66656–67.PubMedPubMedCentralGoogle Scholar
  117. 117.
    Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med. 2010;8:112.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Schmaußer B, Andrulis M, Endrich S, Lee SK, Josenhans C, Müller-Hermelink HK, et al. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol. 2004;136:521–6.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Zarember KA, Godowski PJ. Tissue expression of human Toll-Like Receptors and differential regulation of Toll-Like Receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002;168:554–61.PubMedGoogle Scholar
  120. 120.
    Furrie E, Macfarlane S, Thomson G, Macfarlane GT. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology. 2005;115:565–74.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Guillot L, Medjane S, Le-Barillec K, Balloy V, Danel C, Chignard TM. Response of human pulmonary epithelial cells to LPS involves Toll-like Receptor 4 (TLR4)-dependent signaling pathways. J Biol Chem. 2004;279:2712–8.PubMedGoogle Scholar
  122. 122.
    Pivarcsi A, Bodai L, Réthi B, Kenderessy-Szabó A, Koreck A, Széll M, et al. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol. 2003;15:721–30.PubMedGoogle Scholar
  123. 123.
    Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like receptors for bacterial products. Glia. 2003;43:281–91.PubMedGoogle Scholar
  124. 124.
    Pioli PA, Amiel E, Schaefer TM, Connolly JE, Guyre PM. Differential expression of toll-like receptors 2 and 4 in tissues of the human female reproductive tract. Society. 2004;72:5799–806.Google Scholar
  125. 125.
    Schmaußer B, Andrulis M, Endrich S, Müller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol. 2005;295:179–85.PubMedGoogle Scholar
  126. 126.
    Fernandez-garcia B, Eiro N, Gonza S, Aguirre A, Gonza LO, Casar M, et al. Clinical significance of Toll-like Receptor 3, 4, and 9 in gastric cancer. J Immunother. 2014;37:77–83.PubMedGoogle Scholar
  127. 127.
    Pimentel-Nunes P, Afonso L, Lopes P, Roncon-Albuquerque R, Gonçalves N, Henrique R, et al. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res. 2011;17:677–83.PubMedGoogle Scholar
  128. 128.
    Yuan X, Zhou Y, Wang W, Li J, Xie G, Zhao Y, et al. Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis. 2013;4:e794.PubMedPubMedCentralGoogle Scholar
  129. 129.
    Chen G, Xu M, Chen J, Hong L, Lin W, Zhao S, et al. Clinicopathological features and increased expression of toll-like receptor 4 of gastric cardia cancer in a high-risk Chinese population. J Immunol Res. 2018;2018:7132868.PubMedPubMedCentralGoogle Scholar
  130. 130.
    Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer. 2010;102:908–15.PubMedPubMedCentralGoogle Scholar
  131. 131.
    Xu H, Wu Q, Dang S, Jin M, Xu J, Cheng Y, et al. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One. 2011;6:1–11.Google Scholar
  132. 132.
    Lu CC, Kuo HC, Wang FS, Jou MH, Lee KC, Chuang JH. Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci. 2014;16:159–77.PubMedPubMedCentralGoogle Scholar
  133. 133.
    Simiantonaki N, Kurzik-Dumke U, Karyofylli G, Jayasinghe C, Michel-Schmidt R, Kirkpatrick CJ. Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. Int J Mol Med. 2007;20:21–9.PubMedGoogle Scholar
  134. 134.
    Paarnio K, Väyrynen S, Klintrup K, Ohtonen P, Mäkinen MJ, Mäkelä J, et al. Divergent expression of bacterial wall sensing toll-like receptors 2 and 4 in colorectal cancer. World J Gastroenterol. 2017;23:4831–8.PubMedPubMedCentralGoogle Scholar
  135. 135.
    Nihon-Yanagi Y, Terai K, Murano T, Matsumoto T, Okazumi S. Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer. Cancer Immunol Immunother. 2012;61:71–7.PubMedGoogle Scholar
  136. 136.
    Tchórzewski M, Lewkowicz P, Dziki A, Tchórzewski H. Expression of toll-like receptors on human rectal adenocarcinoma cells. Arch Immunol Ther Exp. 2014;62:247–51.Google Scholar
  137. 137.
    Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res. 2009;29:2473–8.PubMedPubMedCentralGoogle Scholar
  138. 138.
    Eiro N, Gonzalez L, Gonzalez LO, Fernandez-Garcia B, Andicoechea A, Barbon E, et al. Toll-like receptor-4 expression by stromal fibroblasts is associated with poor prognosis in colorectal cancer. J Immunother. 2013;36:342–9.PubMedGoogle Scholar
  139. 139.
    Hasimu A, Ge L, Li QZ, Zhang RP, Guo X. Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer. 2011;30:344–50.PubMedPubMedCentralGoogle Scholar
  140. 140.
    Wang Y, Weng Y, Shi Y, Xia X, Wang S, Duan H. Expression and functional analysis of Toll-like receptor 4 in human cervical carcinoma. J Membr Biol. 2014;247:591–9.PubMedGoogle Scholar
  141. 141.
    Zhang H, Zhang S. The expression of Foxp3 and TLR4 in cervical cancer: association with immune escape and clinical pathology. Arch Gynecol Obstet. 2017;295:705–12.PubMedGoogle Scholar
  142. 142.
    Werner J, Decarlo CA, Escott N, Zehbe I, Ulanova M. Expression of integrins and Toll-like receptors in cervical cancer: effect of infectious agents. Innate Immun. 2012;18:55–69.PubMedGoogle Scholar
  143. 143.
    Yu L, Wang L, Li M, Zhong J, Wang Z, Chen S. Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother. 2010;59:1021–8.PubMedGoogle Scholar
  144. 144.
    Allhorn S, Böing C, Koch AA, Kimmig R, Gashaw I. TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol. 2008;6:1–11.Google Scholar
  145. 145.
    Chen X, Zhao F, Zhang H, Zhu Y, Wu K, Tan G. Significance of TLR4/MyD88 expression in breast cancer. Int J Clin Exp Pathol. 2015;8:7034–9.PubMedPubMedCentralGoogle Scholar
  146. 146.
    Yang H, Wang B, Wang T, Xu L, He C, Wen H, et al. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS One. 2014;9:1–11.Google Scholar
  147. 147.
    Mehmeti M, Allaoui R, Bergenfelz C, Saal LH, Ethier SP, Johansson ME, et al. Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Res. 2015;17:130.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Ma FJ, Liu ZB, Hu X, Ling H, Li S, Wu J, et al. Prognostic value of myeloid differentiation primary response 88 and toll-like receptor 4 in breast cancer patients. PLoS One. 2014;9:e111639.PubMedPubMedCentralGoogle Scholar
  149. 149.
    Wang X, Yu X, Wang Q, Lu Y, Chen H. Expression and clinical significance of SATB1 and TLR4 in breast cancer. Oncol Lett. 2017;14:3611–5.PubMedPubMedCentralGoogle Scholar
  150. 150.
    Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 2010;29:92.PubMedPubMedCentralGoogle Scholar
  151. 151.
    Zhao Y, Kong X, Li X, Yan S, Yuan C, Hu W, et al. Metadherin mediates lipopolysaccharide-induced migration and invasion of breast cancer cells. PLoS One. 2011;6:e17582.Google Scholar
  152. 152.
    Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther. 2013;12:1676–87.PubMedPubMedCentralGoogle Scholar
  153. 153.
    González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, González-Quintana JMVF. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28:4353.PubMedPubMedCentralGoogle Scholar
  155. 155.
    Luo XZ, He QZ, Wang K. Expression of Toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade. Int J Clin Exp Med. 2015;8:14323–7.PubMedPubMedCentralGoogle Scholar
  156. 156.
    Kim KH, Jo MS, Suh DS, Yoon MS, Shin DH, Lee JH, et al. Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol. 2012;10:193.PubMedPubMedCentralGoogle Scholar
  157. 157.
    Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859–68.PubMedGoogle Scholar
  158. 158.
    Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother. 2009;58:1375–85.PubMedGoogle Scholar
  159. 159.
    Woods DC, White YA, Dau CJAL. TLR4 activates NF-κB in human ovarian granulosa tumor cells. Biochem Biophys Res Commun. 2011;409:675–80.PubMedPubMedCentralGoogle Scholar
  160. 160.
    Wang AC, Su QB, Wu FX, Zhang XL, Liu PS. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Investig. 2009;39:157–64.Google Scholar
  161. 161.
    Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, et al. MyD88 and TLR4 expression in epithelial ovarian cancer. Mayo Clin Proc. 2018;93:307–20.PubMedPubMedCentralGoogle Scholar
  162. 162.
    Szczepanski M, Stelmachowska M, Stryczynski L, Golusinski W, Samara H, Mozer-Lisewska I, et al. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2007;264:525–30.PubMedGoogle Scholar
  163. 163.
    Ilmarinen T, Hagström J, Haglund C, Auvinen E, Leivo I, Pitkäranta A, et al. Low expression of nuclear toll-like receptor 4 in laryngeal papillomas transforming into squamous cell carcinoma. Otolaryngol Head Neck Surg. 2014;151:785–90.PubMedGoogle Scholar
  164. 164.
    Starska K, Forma E, Bryś M, Głowacka E, Lewy-Trenda I, Lukomski M, et al. The expression of TLR pathway molecules in peripheral blood mononuclear cells and their relationship with tumor invasion and cytokine secretion in laryngeal carcinoma. Adv Med Sci. 2012;56:1–12.Google Scholar
  165. 165.
    Eiró N, Altadill A, Juárez LM, Rodríguez M, González LO, Atienza S, et al. Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: relationship with clinicopathological characteristics and prognosis. Hepatol Res. 2014;44:769–78.PubMedGoogle Scholar
  166. 166.
    Liu WT, Jing YY, Yu GF, Han ZP, Yu DD, Fan QM, et al. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma. Cancer Lett. 2015;358:136–43.PubMedGoogle Scholar
  167. 167.
    Soares JB, Pimentel-Nunes P, Afonso L, Rolanda C, Lopes P, Roncon-Albuquerque R, et al. Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immun. 2012;18:700–8.PubMedGoogle Scholar
  168. 168.
    Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:3745–51.PubMedPubMedCentralGoogle Scholar
  169. 169.
    Verbeek RE, Siersema PD, Ten Kate FJ, Fluiter K, Souza RF, Vleggaar FP, et al. Toll-like receptor 4 activation in Barrett’s esophagus results in a strong increase in COX-2 expression. J Gastroenterol. 2014;49:1121–34.PubMedGoogle Scholar
  170. 170.
    Yang J, Liu D, Khatri KS, Wang J, Zhang G, Meng C, et al. Prognostic value of toll-like receptor 4 and nuclear factor-κBp65 in oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(753–764):e1.Google Scholar
  171. 171.
    Gatti G, Quintar AA, Andreani V, Nicola JP, Maldonado CA, Masini-Repiso AM, et al. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate. 2009;69:1387–97.PubMedGoogle Scholar
  172. 172.
    González-Reyes S, Fernández JM, González LO, Aguirre A, Suárez A, González JM, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 2011;60:217–26.PubMedGoogle Scholar
  173. 173.
    Hua D, Liu M, Cheng Z, Qin X, Zhang H, Chen Y, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol. 2009;46:2876–84.PubMedGoogle Scholar
  174. 174.
    Damasdi M, Kovacs K, Farkas N, Jakab FKG. Down-regulation of Toll-like Receptor TLR4 is associated with HPV DNA integration in penile carcinoma. Anticancer Res. 2017;37:5515–9.PubMedGoogle Scholar
  175. 175.
    Alvarado AG, Thiagarajan PS, Mulkearns-Hubert EE, Silver DJ, Hale JS, Alban TJ, et al. Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression. Cell Stem Cell. 2017;20(450–461):e4.Google Scholar
  176. 176.
    Climate B, Dyck V, Phylogenies TF, Compare EP, Singh SK, Hawkins C, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.Google Scholar
  177. 177.
    Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60.PubMedGoogle Scholar
  178. 178.
    Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SGPL. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488:522–6.PubMedPubMedCentralGoogle Scholar
  179. 179.
    Ahmed S, Moawad M, Elhefny R, Abdullatif M. Is toll like receptor 4 a common pathway hypothesis for development of lung cancer and idiopathic pulmonary fibrosis? Egypt J Chest Dis Tuberc. 2016;65:289–94.Google Scholar
  180. 180.
    Zhang YB, He FL, Fang M, Hua TF, Hu BD, Zhang ZH, et al. Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep. 2009;36:1475–81.PubMedGoogle Scholar
  181. 181.
    Samara KD, Antoniou KM, Karagiannis K, Margaritopoulos G, Lasithiotaki I, Koutala E, et al. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. Int J Oncol. 2012;40:1397–404.PubMedGoogle Scholar
  182. 182.
    He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44:2850–9.PubMedGoogle Scholar
  183. 183.
    Fu H, Li C, Yang W, Gai X, Jia T, Lei Y, et al. FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape. Acta Histochem. 2013;115:151–7.PubMedGoogle Scholar
  184. 184.
    Awasthi S. Toll-like receptor-4 modulation for cancer immunotherapy. Front Immunol. 2014;5:1–5.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.P D Patel Institute of Applied SciencesCharotar University of Science and Technology (CHARUSAT)AnandIndia

Personalised recommendations